Blinatumomab [BLI2]
The treatment of relapsed/refractory Philadelphia negative B-precursor acute lymphoblastic leukaemia in CHILD patients
- An application is being made and the first cycle of systemic anti-cancer therapy with blinatumomab will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.
- The patient is a child and ONE of the following applies: OPTION 1 - The patient is post pubescent. OPTION 2 - The patient is pre pubescent Please choose correct option
- Option A
- Option B NB. There is a separate Blueteq form to be used for blinatumomab in this indication in adults.
- The patient has relapsed or refractory Philadelphia negative acute lymphoblastic leukaemia (ALL).
- The patient has been previously treated with intensive combination chemotherapy as initial treatment with or without subsequent salvage therapy.
- Blinatumomab is being requested by and administered in principal treatment centres only.
- The use of the blinatumomab has been discussed at a multidisciplinary team (MDT) meeting which must include at least two consultants in the subspecialty with active and credible expertise in the relevant field of whom at least one must be a consultant paediatrician. The MDT should include a paediatric pharmacist and other professional groups appropriate to the disease area.
- The patient has a performance status of 0 - 2.
- A maximum of 5 cycles of treatment with blinatumomab will be administered.
- The use of blinatumomab in this indication is exempt from the NHS England Treatment Break policy.
- Trust policy regarding unlicensed treatments has been followed as blinatumomab is not fully licensed in this indication in children.
- Blinatumomab should otherwise be used as set out in its Summary of Product Characteristics (SPC).
NHS funded From: 26 September 2017
Additional information
Current Form Version
Important
This is an older version of the form. To view the most up to date form follow this link